Valion Bio, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-8.9M | $-5.7M | $-8.2M | $-10.1M | $-8.5M |
| Depreciation & Amortization | — | $3.0K | $8.0K | $10.0K | — |
| Depreciation | $5.0K | $3.0K | $8.0K | $10.0K | $8.0K |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $564.0K | $229.0K | $271.0K | $398.0K | $57.0K |
| Net Cash from Operating Activities | $-7.0M | $-5.7M | $-8.5M | $-8.9M | $-5.6M |
| Investing Activities | |||||
| Capital Expenditures | $38.0K | $0 | $118.0K | $11.0K | — |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-705.0K | $0 | $-118.0K | $-11.0K | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $18.3M | $4.3M | $8.5M | $-528.0K | $17.5M |
| Net Change in Cash | $10.6M | $-1.4M | $-122.0K | $-9.5M | $11.9M |
| Free Cash Flow | $-7.0M | $-5.7M | $-8.6M | $-8.9M | — |